<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963727</url>
  </required_header>
  <id_info>
    <org_study_id>AlloKneeUJCTC</org_study_id>
    <nct_id>NCT02963727</nct_id>
  </id_info>
  <brief_title>Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis</brief_title>
  <official_title>Knee Osteoarthrosis (KOA) in Jordanian Patients: a Phase I Dose-finding Study Using Wharton Jelly Derived Mesenchymal Stem Cells (WJMSC) for Advanced Stage III and IV KOA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanan Jafar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) will be injected in patients diagnosed
      with Knee osteoarthrosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ten patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according
      to strict inclusion and exclusion criteria. These patients will be injected with Wharton
      Jelly derived Mesenchymal Stem Cells. Then, they are followed by clinical assessment,
      laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the safety and tolerability of the intra articular injection</measure>
    <time_frame>6 months</time_frame>
    <description>patients will be monitored for any adverse events resulting from the intraarticular injection of WJMSC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the efficacy of intra-articular injection of WJMSC</measure>
    <time_frame>12 months</time_frame>
    <description>The efficacy of the intra-articular injection of WJMSC will be assessed by Magnetic Resonance Imaging (MRI).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Knee Osteoarthrosis</condition>
  <arm_group>
    <arm_group_label>Wharton Jelly mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Wharton Jelly derived mesenchymal stem cell</intervention_name>
    <description>Intra-articular Wharton Jelly derived mesenchymal stem cell injection.</description>
    <arm_group_label>Wharton Jelly mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe KOA stage III or IV by Laurance &amp; Kellgren staging as judged by
             Posterioranterior (PA) Xray of the knee joint.

          -  Willing to participate by signing the informed consent

        Exclusion Criteria:

          1. Sublaxation beyond 20 degrees of the bones of the knee joint

          2. Oral anticoagulants or heparin therapy

          3. Heart failure or arrhythmia

          4. Body Mass Index &gt; 35

          5. Uncontrolled Diabetes Mellitus.

          6. Evidence of Infectious Diseases.

          7. Active infection

          8. Malignancy

          9. Pregnancy

         10. Anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia less than
             3000.

         11. Unreliable patients

         12. Non-resident in Jordan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdallah Awidi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cell Therapy Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanan Jafar, PhD</last_name>
    <phone>00962798871087</phone>
    <email>hanan.jafar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cell Therapy Center</name>
      <address>
        <city>Amman</city>
        <zip>11942</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdalla Awidi, MD</last_name>
      <phone>0096265355000</phone>
      <phone_ext>23960</phone_ext>
      <email>abdalla.awidi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Hanan Jafar</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>osteoarthrosis</keyword>
  <keyword>Knee</keyword>
  <keyword>Wharton Jelly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

